Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors

A Pawłowska, A Rekowska, W Kuryło… - International journal of …, 2023 - mdpi.com
The standard treatment of ovarian cancer (OC) patients, including debulking surgery and
first-line chemotherapy, is unsatisfactory because of recurrent episodes in the majority …

Pathological role of LncRNAs in immune-related disease via regulation of T regulatory cells

SIS Al-Hawary, K Kashikova, EM Ioffe… - … -Research and Practice, 2023 - Elsevier
Human regulatory T cells (Tregs) are essential in pathogenesis of several diseases such as
autoimmune diseases and cancers, and their imbalances may be promoting factor in these …

[HTML][HTML] Limitations and potential of immunotherapy in ovarian cancer

S Kumar, S Acharya, M Karthikeyan, P Biswas… - Frontiers in …, 2024 - frontiersin.org
Ovarian cancer (OC) is the third most common gynecological cancer and alone has an
emergence rate of approximately 308,069 cases worldwide (2020) with dire survival rates …

Engineering strategies to optimise adoptive cell therapy in ovarian cancer

C Guerra, M Kalaitsidou, G Kueberuwa… - Cancer Treatment …, 2023 - Elsevier
Ovarian cancer is amongst the ten most common cancer types in women, and it is one of the
leading causes of death. Despite the promising results of targeted therapies, including anti …

[HTML][HTML] Immune pathway through endometriosis to ovarian cancer

MS Calmon, FFB Lemos, MS Luz… - World Journal of …, 2024 - ncbi.nlm.nih.gov
Endometriosis is an estrogen-dependent inflammatory disease, defined by the presence of
functional endometrial tissue outside of the uterine cavity. This disease is one of the main …

Necrosis-associated long noncoding RNA for predicting prognosis in hepatocellular carcinoma

X Wang, J Yang, Z Ma, Z Hu - 2023 - researchsquare.com
Background and aim Histiocellular carcinoma (HCC) ranks second in the world's most
deadly diseases, with a high mortality rate. Unlike apoptosis, necroptosis causes the release …